Baird raised the firm’s price target on Quest Diagnostics (DGX) to $194 from $191 and keeps an Outperform rating on the shares.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics: Resilience and Growth Potential Amidst Macroeconomic Challenges
- Quest Diagnostics price target raised to $185 from $175 at Barclays
- Quest Diagnostics Reports Strong Q1 2025 Results
- Quest Diagnostics Reports Strong Growth in Earnings Call
- Early notable gainers among liquid option names on April 22nd